

# CITATION REPORT

List of articles citing

## Targeting histone lysine methylation in cancer

DOI: 10.1016/j.pharmthera.2015.01.002

Pharmacology & Therapeutics, 2015, 150, 1-22.

**Source:** <https://exaly.com/paper-pdf/61654582/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
155	Post-translational control of transcription factors: methylation ranks highly. <b>2015</b> , 282, 4450-65		32
154	Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression. <b>2015</b> , 15, 801		27
153	Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140168	3.7	12
152	Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. <b>2015</b> , 7, 1379-96		32
151	Histone profiles in cancer. <i>Pharmacology &amp; Therapeutics</i> , <b>2015</b> , 154, 87-109	13.9	5
150	Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. <b>2015</b> , 99, 248-57		67
149	Epigenetics: Disrupting histone lysine methylation. <b>2015</b> , 11, 552-4		1
148	The dengue virus NS5 protein as a target for drug discovery. <b>2015</b> , 119, 57-67		120
147	Concise Review: Energy Metabolites: Key Mediators of the Epigenetic State of Pluripotency. <b>2015</b> , 33, 2374-80		32
146	Epigenetic regulation by histone demethylases in hypoxia. <b>2015</b> , 7, 791-811		101
145	The effects of SUUR protein suggest its role in repressive chromatin renewal during replication in <i>Drosophila</i> . <b>2015</b> , 6, 249-53		7
144	Histone methylation modifiers in cellular signaling pathways. <b>2015</b> , 72, 4577-92		75
143	Lysine Demethylases. <b>2016</b> , 179-194		3
142	Histone Methylation Modifiers in Medical Therapeutics. <b>2016</b> , 705-729		1
141	Pharmacological and Therapeutic Targeting of Epigenetic Regulators. <b>2016</b> , 387-401		
140	Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	19
139	Methyltransferase-Glo: a universal, bioluminescent and homogenous assay for monitoring all classes of methyltransferases. <b>2016</b> , 8, 321-39		42

138	Functional AdoMet Isosteres Resistant to Classical AdoMet Degradation Pathways. <i>ACS Chemical Biology</i> , <b>2016</b> , 11, 2484-91	4.9	27
137	Intrinsic protein disorder in histone lysine methylation. <b>2016</b> , 11, 30		14
136	Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. <b>2016</b> , 9, 49		86
135	An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. <b>2016</b> , 12, 531-8		188
134	Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. <i>Clinical Epigenetics</i> , <b>2016</b> , 8, 57	7.7	256
133	Identification of potent, selective KDM5 inhibitors. <b>2016</b> , 26, 4350-4		33
132	4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A. <b>2016</b> , 11, 2063-83		11
131	Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9. <b>2016</b> , 24, 4318-4323		10
130	KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis. <b>2016</b> , 16, 3016-3027		45
129	Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)pyridin-4-yl)ethanamine (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 9928-9941	8.5	130
128	Purification, Biochemical Analysis, and Structure Determination of JmjC Lysine Demethylases. <b>2016</b> , 573, 279-301		3
127	Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket. <i>ACS Medicinal Chemistry Letters</i> , <b>2016</b> , 7, 730-4	4.3	35
126	The promise of epigenomic therapeutics in pancreatic cancer. <b>2016</b> , 8, 831-42		34
125	Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy. <b>2016</b> , 130, 55-111		54
124	Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. <b>2016</b> , 76, 1975-88		74
123	Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases. <b>2016</b> , 8, 1553-71		12
122	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 1501-17	8.3	50
121	EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes. <b>2016</b> , 15, 287-98		43

120	Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy. <b>2016</b> , 8, 285-305		21
119	Chromatin deregulation in disease. <b>2016</b> , 125, 75-93		68
118	Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. <b>2017</b> , 12, 353-369		27
117	Epigenetics in cancer stem cells. <i>Molecular Cancer</i> , <b>2017</b> , 16, 29	42.1	195
116	A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. <b>2017</b> , 25, 218-231		50
115	Assessing histone demethylase inhibitors in cells: lessons learned. <b>2017</b> , 10, 9		31
114	Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer. <b>2017</b> , 137, 12-19		17
113	Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 1673-1692	8.3	47
112	Developing Spindlin1 small-molecule inhibitors by using protein microarrays. <b>2017</b> , 13, 750-756		35
111	Probing lysine mono-methylation in histone H3 tail peptides with an abiotic receptor coupled to a non-plasmonic resonator. <b>2017</b> , 9, 8639-8646		20
110	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. <b>2017</b> , 8, 15424		74
109	Role of epigenetics in tumor induction by non-genotoxic carcinogens. <b>2017</b> , 6, 42-49		1
108	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. <b>2017</b> , 3, 360-373		7
107	Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates. <b>2017</b> , 429, 2895-2906		22
106	KDM4A regulates HIF-1 levels through H3K9me3. <b>2017</b> , 7, 11094		22
105	The Molecular Basis of Histone Demethylation. <b>2017</b> , 151-219		6
104	Histone demethylase PHF8 regulates hypoxia signaling through HIF1 $\alpha$ and H3K4me3. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , <b>2017</b> , 1860, 1002-1012	6	9
103	Systematic discovery of genetic modulation by Jumonji histone demethylases in <i>Drosophila</i> . <b>2017</b> , 7, 5240		17

102	Investigation of Trimethyllysine Binding by the HP1 Chromodomain via Unnatural Amino Acid Mutagenesis. <b>2017</b> , 139, 17253-17256		18
101	Inhibitors of Epigenetic Regulation in Cancer. <b>2017</b> , 281-307		
100	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. <b>2017</b> , 57, 331-342		27
99	Rethinking the Epigenetic Framework to Unravel the Molecular Pathology of Schizophrenia. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	9
98	Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival. <i>Oncotarget</i> , <b>2017</b> , 8, 62081-62098	3.3	22
97	KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. <b>2018</b> , 19, e489-e501		20
96	Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma. <b>2018</b> , 77, 166-174		21
95	Transient epigenomic changes during pregnancy and early postpartum in women with and without type 2 diabetes. <b>2018</b> , 10, 419-431		3
94	Epigenetic processes in sporadic parathyroid neoplasms. <b>2018</b> , 469, 54-59		8
93	Inhibitors of Protein Methyltransferases and Demethylases. <b>2018</b> , 118, 989-1068		144
92	Oncogenic Epstein-Barr virus recruits Nm23-H1 to regulate chromatin modifiers. <b>2018</b> , 98, 258-268		5
91	Lysine methylation signaling in pancreatic cancer. <b>2018</b> , 30, 30-37		8
90	High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 13750-13765	5.4	27
89	Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges. <b>2018</b> , 16, 211-223		34
88	The A-Z of Zika drug discovery. <b>2018</b> , 23, 1833-1847		38
87	Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor. <i>Clinical Epigenetics</i> , <b>2018</b> , 10, 107	7.7	26
86	EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small-Cell Lung Cancer. <b>2018</b> , 12, 309-318		16
85	Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension. <b>2019</b> , 597, 1103-1119		19

84	The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	8
83	Insights for the design of protein lysine methyltransferase G9a inhibitors. <b>2019</b> , 11, 993-1014		15
82	Genome-wide CHIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells. <b>2019</b> , 18, 872-881		6
81	The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases. <i>ACS Chemical Biology</i> , <b>2019</b> , 14, 1737-1750	4.9	11
80	Weighted correlation network analysis of triple-negative breast cancer progression: Identifying specific modules and hub genes based on the GEO and TCGA database. <b>2019</b> , 18, 1207-1217		3
79	Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer. <b>2019</b> , 15, 140-152		22
78	Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases. <b>2019</b> , 14, 1828-1839		7
77	Comprehensive profiling of JMJD3 in gastric cancer and its influence on patient survival. <b>2019</b> , 9, 868		16
76	Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines. <i>Cancers</i> , <b>2019</b> , 11,	6.6	24
75	H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy. <b>2019</b> , 8,		22
74	The molecular landscape of histone lysine methyltransferases and demethylases in non-small cell lung cancer. <b>2019</b> , 16, 922-930		7
73	Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. <b>2019</b> , 116, 108997		10
72	Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications. <b>2019</b> , 9, 8189		10
71	Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B. <b>2019</b> , 24,		15
70	Pathogenic and Therapeutic Role of H3K4 Family of Methylases and Demethylases in Cancers. <b>2019</b> , 34, 123-132		9
69	Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends. <b>2019</b> , 11, 901-921		16
68	Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil. <b>2019</b> , 21, 557-570		20
67	Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers. <b>2019</b> , 88, 102929		20

66	Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors. <b>2019</b> , 29, 1173-1176		5
65	Role of physical exercise in the regulation of epigenetic mechanisms in inflammation, cancer, neurodegenerative diseases, and aging process. <b>2019</b> , 234, 14852		25
64	Histone Methyltransferases as Therapeutic Targets for Kidney Diseases. <b>2019</b> , 10, 1393		16
63	Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations. <b>2019</b> , 37, 3482-3495		9
62	The Role of DNA/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors. <i>Cancers</i> , <b>2018</b> , 11,	6.6	13
61	Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers. <b>2019</b> , 105, 137-149		14
60	Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking. <b>2019</b> , 29, 544-548		3
59	Targeting Cancer Cell Dormancy. <b>2019</b> , 40, 128-141		109
58	MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A. <b>2019</b> , 120, 4987-4997		17
57	Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines. <b>2020</b> , 213, 103614		1
56	Hypoxia-Inducible Lysine Methyltransferases: G9a and GLP Hypoxic Regulation, Non-histone Substrate Modification, and Pathological Relevance. <b>2020</b> , 11, 579636		6
55	Genome-wide identification and transcriptional modulation of histone variants and modification related genes in the low pH-exposed marine rotifer <i>Brachionus koreanus</i> . <i>Comparative Biochemistry and Physiology Part D: Genomics and Proteomics</i> , <b>2020</b> , 36, 100748	2	
54	Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , <b>2020</b> , 11, 1213-1220	4.3	10
53	Suppression of Mll1-Complex by Stat3/Cebp $\beta$ Induced miR-21a/21b/181b Maintains the Accumulation, Homeostasis, and Immunosuppressive Function of Polymorphonuclear Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , <b>2020</b> , 204, 3400-3415	5.3	5
52	Isoform-Specific Lysine Methylation of ROR $\alpha$ by SETD7 Is Required for Association of the TIP60 Coactivator Complex in Prostate Cancer Progression. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
51	Verification of EZH2 as a druggable target in metastatic uveal melanoma. <i>Molecular Cancer</i> , <b>2020</b> , 19, 52	42.1	9
50	Targeting epigenetics in cancer: therapeutic potential of flavonoids. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 61, 1616-1639	11.5	17
49	Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt/ $\beta$ -catenin pathway. <i>Life Sciences</i> , <b>2021</b> , 264, 118726	6.8	1

48	Histone lysine demethylase inhibitor (HDMI) as chemo-sensitizing agent. <b>2021</b> , 41-55		
47	EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells. <i>Journal of Cancer</i> , <b>2021</b> , 12, 1011-1022	4.5	3
46	Targeting histone lysine methyltransferases for drug sensitization. <b>2021</b> , 57-67		
45	Lysine-specific demethylase 1 (LSD1) serves as an potential epigenetic determinant to regulate inflammatory responses in mastitis. <i>International Immunopharmacology</i> , <b>2021</b> , 91, 107324	5.8	1
44	Prognosis model of colorectal cancer patients based on , , and mutations. <i>Journal of Gastrointestinal Oncology</i> , <b>2021</b> , 12, 79-88	2.8	0
43	Function and Mechanism of Novel Histone Posttranslational Modifications in Health and Disease. <i>BioMed Research International</i> , <b>2021</b> , 2021, 6635225	3	5
42	KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma. <i>Biochemical and Biophysical Research Communications</i> , <b>2021</b> , 550, 77-83	3.4	12
41	Advances in epigenetic therapeutics with focus on solid tumors. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 83	7.7	14
40	The New Serum-Free OptiPASS Medium in Cold and Oxygen-Free Conditions: An Innovative Conservation Method for the Preservation of MDA-MB-231 Triple Negative Breast Cancer Spheroids. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
39	Metabolic reprogramming and epigenetic modifications on the path to cancer. <i>Protein and Cell</i> , <b>2021</b> , 1	7.2	25
38	Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
37	The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
36	Determines Mesothelioma Cell Fate to EZH2 Inhibition. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 678447	5.3	4
35	Ready, SET, Go: Post-translational regulation of the histone lysine methylation network in budding yeast. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 297, 100939	5.4	4
34	Histone methylation in pancreatic cancer and its clinical implications. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 6004-6024	5.6	2
33	Mechanistic insights into KDM4A driven genomic instability. <i>Biochemical Society Transactions</i> , <b>2021</b> , 49, 93-105	5.1	2
32	A Chemical Acetylation-Based Mass Spectrometry Platform for Histone Methylation Profiling. <i>Molecular and Cellular Proteomics</i> , <b>2021</b> , 20, 100067	7.6	2
31	Histone methylation modifiers in medical therapeutics. <b>2021</b> , 693-720		



30	Epigenetic Regulation of Chromatin in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1210, 379-407	3.6	6
29	Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156599	3.7	12
28	Using Fragment Based Drug Discovery to Target Epigenetic Regulators in Cancer. <i>MOJ Bioequivalence &amp; Bioavailability</i> , <b>2017</b> , 4,		1
27	Different Mechanisms of Epigenetic Regulation of Gene Expression. <i>MOJ Cell Science &amp; Report</i> , <b>2015</b> , 2,		3
26	Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. <i>Oncotarget</i> , <b>2017</b> , 8, 3396-3411	3.3	47
25	An Overview of Chromatin-Regulating Proteins in Cells. <i>Current Protein and Peptide Science</i> , <b>2016</b> , 17, 401-10	2.8	41
24	EZH2-mediated epigenetic suppression of lncRNA PCAT18 predicts a poor prognosis and regulates the expression of p16 by interacting with miR-570a-3p in gastric cancer. <i>Journal of Cancer</i> , <b>2021</b> , 12, 7069-7078 <sup>1</sup>	4.5	1
23	A computer aided drug discovery based discovery of lead-like compounds against KDM5A for cancers using pharmacophore modeling and high-throughput virtual screening. <i>Proteins: Structure, Function and Bioinformatics</i> , <b>2021</b> ,	4.2	2
22	Epigenetic Signaling of Cancer Stem Cells During Inflammation. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 772211	5.7	4
21	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 15170-15188 <sup>8,3</sup>	8.3	3
20	Small Molecule Inhibitors of the Human Histone Lysine Methyltransferase NSD2 / WHSC1 / MMSET Identified from a Quantitative High-Throughput Screen with Nucleosome Substrate.		1
19	Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6
18	Histone demethylase JMJD1C regulates esophageal cancer proliferation Via YAP1 signaling. <i>American Journal of Cancer Research</i> , <b>2017</b> , 7, 115-124	4.4	11
17	Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer. <i>American Journal of Translational Research (discontinued)</i> , <b>2019</b> , 11, 1145-1153 <sup>3</sup>		12
16	Systematic Variation of Both the Aromatic Cage and Dialkyllysine via GCE-SAR Reveal Mechanistic Insights in CBX5 Reader Protein Binding.. <i>Journal of Medicinal Chemistry</i> , <b>2022</b> ,	8.3	1
15	The CBL-LSD1-CXCL8 axis regulates methionine metabolism in glioma.. <i>Cytokine</i> , <b>2022</b> , 151, 155789	4	0
14	Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics.. <i>ACS Chemical Biology</i> , <b>2022</b> ,	4.9	0
13	DOT1L Epigenetically Induces the Expression Level of FoxM1 through H3K79me2 and Affects the Malignant Behaviors of Head and Neck Squamous Cell Carcinoma Cells. <i>Journal of Hard Tissue Biology</i> , <b>2022</b> , 31, 101-108	0.4	

12	Screening for Small-Molecule Inhibitors of Histone Methyltransferases. <i>Methods in Molecular Biology</i> , <b>2022</b> , 477-490	1.4	
11	Chemical biology and pharmacology of histone lysine methylation inhibitors. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , <b>2022</b> , 194840	6	2
10	Tumor cell dormancy: Molecular mechanisms, and pharmacological approaches to target dormant cells for countering tumor. <b>2022</b> , 75, 103645		0
9	Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. <b>2022</b> , 10, 1448		0
8	DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine.		0
7	SETD1A promotes the proliferation and glycolysis of nasopharyngeal carcinoma cells by activating the PI3K/Akt pathway. <b>2022</b> , 17, 1849-1859		0
6	Lysine succinylation, the metabolic bridge between cancer and immunity. <b>2022</b> ,		0
5	Modulation of epigenetic methylation enzymes by synthetic and natural agents. <b>2023</b> , 325-357		0
4	Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy. <b>2023</b> , 28, 103519		0
3	Modulating epigenetic modifications for cancer therapy (Review). <b>2023</b> , 49,		1
2	Epigenetics in cancer development, diagnosis and therapy. <b>2023</b> ,		0
1	Therapeutic vulnerabilities of cancer stem cells and effects of natural products.		0